These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 11838627

  • 1. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study.
    Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewenthal U, Kotler M.
    J Clin Psychiatry; 2002 Jan; 63(1):54-8. PubMed ID: 11838627
    [Abstract] [Full Text] [Related]

  • 2. [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders].
    Miodownik C, Cohen H, Kotler M, Lerner V.
    Harefuah; 2003 Sep; 142(8-9):592-6, 647. PubMed ID: 14518160
    [Abstract] [Full Text] [Related]

  • 3. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.
    Lerner V, Bergman J, Statsenko N, Miodownik C.
    J Clin Psychiatry; 2004 Nov; 65(11):1550-4. PubMed ID: 15554771
    [Abstract] [Full Text] [Related]

  • 4. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS.
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [Abstract] [Full Text] [Related]

  • 6. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [Abstract] [Full Text] [Related]

  • 7. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M, Levi L, Burshtein S, Hagin M, Matei VP, Podea D, Micluția I, Tiugan A, Păcală B, Grecu IG, Noy A, Zamora D, Davis JM.
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [Abstract] [Full Text] [Related]

  • 8. Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Kardashev A, Ratner Y, Ritsner MS.
    Clin Schizophr Relat Psychoses; 2018 Jul; 12(1):31-41. PubMed ID: 26218236
    [Abstract] [Full Text] [Related]

  • 9. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, Gurvich C, Gilbert H, Berk M, Davis SR.
    JAMA Psychiatry; 2016 Sep 01; 73(9):947-54. PubMed ID: 27438995
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan 01; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 11. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
    Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela BA, Witztum E.
    J Clin Psychiatry; 2007 Nov 01; 68(11):1648-54. PubMed ID: 18052557
    [Abstract] [Full Text] [Related]

  • 12. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
    Shiloh R, Weizman A, Weizer N, Dorfman-Etrog P, Munitz H.
    Harefuah; 2001 May 01; 140(5):369-73, 456. PubMed ID: 11419053
    [Abstract] [Full Text] [Related]

  • 13. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study.
    Miodownik C, Lerner V, Statsenko N, Dwolatzky T, Nemets B, Berzak E, Bergman J.
    Clin Neuropharmacol; 2006 May 01; 29(2):68-72. PubMed ID: 16614537
    [Abstract] [Full Text] [Related]

  • 14. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.
    Arch Gen Psychiatry; 2003 Jul 01; 60(7):681-90. PubMed ID: 12860772
    [Abstract] [Full Text] [Related]

  • 15. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO.
    Am J Psychiatry; 2004 Oct 01; 161(10):1837-47. PubMed ID: 15465981
    [Abstract] [Full Text] [Related]

  • 16. Serum vitamin B6 in schizophrenic and schizoaffective patients with and without tardive dyskinesia.
    Miodownik C, Lerner V, Cohen H, Kotler M.
    Clin Neuropharmacol; 2000 Oct 01; 23(4):212-5. PubMed ID: 11020126
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
    Vieta E, Herraiz M, Fernández A, Gastó C, Benabarre A, Colom F, Martínez-Arán A, Reinares M.
    J Clin Psychiatry; 2001 Aug 01; 62(8):623-30. PubMed ID: 11561935
    [Abstract] [Full Text] [Related]

  • 19. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
    Stauffer VL, Song G, Kinon BJ, Ascher-Svanum H, Chen L, Feldman PD, Conley RR.
    Schizophr Res; 2012 Feb 01; 134(2-3):195-201. PubMed ID: 22019076
    [Abstract] [Full Text] [Related]

  • 20. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study.
    Nikbakhat MR, Arabzadeh S, Zeinoddini A, Khalili Z, Rezaei F, Mohammadinejad P, Ghaleiha A, Akhondzadeh S.
    Pharmacopsychiatry; 2016 Jul 01; 49(4):162-9. PubMed ID: 26902281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.